Prelude Therapeutics Incorporated (PRLD) Revenue History
Annual and quarterly revenue from 2018 to 2025
Compound Annual Growth Rate (CAGR)
Loading revenue history...
PRLD Revenue Growth
PRLD Revenue Analysis (2018–2025)
As of May 8, 2026, Prelude Therapeutics Incorporated (PRLD) generated trailing twelve-month (TTM) revenue of $12.1 million, reflecting explosive growth of +41.0% year-over-year. The most recent quarter (Q4 2025) recorded $5.6 million in revenue, down 13.2% sequentially.
Looking at the longer-term picture, PRLD's historical revenue data shows various trends over time. The company achieved its highest annual revenue of $12.1 million in 2025, representing a new all-time high.
When compared to Healthcare sector peers including KYMR (-12.6% YoY), ARVN (-0.3% YoY), and AUPH (+20.4% YoY), PRLD has outperformed the peer group in terms of revenue growth. Compare PRLD vs KYMR →
PRLD Revenue vs Peers
Revenue metrics vs comparable public companies
| Company | TTM Revenue | YoY Growth | 5Y CAGR | Op. Margin | Compare |
|---|---|---|---|---|---|
| PRLDCurrent | $12M | +41.0% | - | -861.3% | |
 KYMR | $39M | -12.6% | +2.9% | -891.3% | |
 ARVN | $263M | -0.3% | +58.9% | -43.8% | |
 AUPH | $283M | +20.4% | +41.4% | 37.1% |
PRLD Historical Revenue Data (2018–2025)
| Year | Revenue | YoY % | Gross Profit | Gross Margin | Op. Income | Op. Margin |
|---|---|---|---|---|---|---|
| 2025 | $12.1M | +73.4% | $10.4M | 85.9% | $-104,566,000 | -861.3% |
| 2024 | $7.0M | - | $7.0M | 100.0% | $-139,714,000 | -1995.9% |
| 2023 | $0 | - | $0 | - | $-132,276,999 | - |
| 2022 | $0 | - | $0 | - | $-123,540,000 | - |
| 2021 | $0 | - | $0 | - | $-113,735,000 | - |
| 2020 | $0 | - | $0 | - | $-58,763,000 | - |
| 2019 | $0 | - | $0 | - | $-28,109,000 | - |
| 2018 | $0 | - | $-149,000 | - | $-14,975,000 | - |
See PRLD's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs PRLD Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare PRLD vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonPRLD — Frequently Asked Questions
Quick answers to the most common questions about buying PRLD stock.
Is PRLD's revenue growth accelerating or slowing?
PRLD revenue is accelerating at +41.0% year-over-year, exceeding the 5-year CAGR of N/A. TTM revenue reached $12M. Growth momentum has increased versus prior periods.
What is PRLD's long-term revenue growth rate?
Prelude Therapeutics Incorporated's 5-year revenue CAGR of N/A reflects the sustained expansion pattern. Current YoY growth of +41.0% is above this long-term average.
How is PRLD's revenue distributed by segment?
PRLD reports revenue by product line and geographic region. Annual and quarterly breakdowns from 2018-2025 are available for download. Segment mix reveals concentration and diversification trends.